Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical innovator developing therapies for complex medical conditions with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time information about VNDA's sleep-wake disorder treatments, psychiatric therapies, and neurology pipeline. Our curated collection includes FDA decision updates, clinical trial results, financial earnings reports, and partnership announcements – all critical for understanding the company's market position.
Bookmark this page for streamlined tracking of Vanda's progress in antisense oligonucleotide research and commercialization efforts. Regular updates ensure you stay informed about HETLIOZ developments, Fanapt market performance, and emerging therapies in the company's clinical pipeline.
Cycle Pharmaceuticals has reaffirmed its proposal to acquire Vanda Pharmaceuticals (NASDAQ: VNDA) for $8.00 per share in an all-cash transaction. This offer represents an 80% premium to Vanda's closing share price on October 11, 2024, and values the company at $488 million on a fully diluted basis.
Cycle criticizes Vanda's board for refusing to engage and for implementing bylaw amendments that Cycle views as entrenching efforts. The proposal comes after Vanda's recent failure to receive FDA approval for tradipitant following an unsuccessful Phase 3 trial.
Cycle urges Vanda shareholders to express their views on the proposal to the independent directors of Vanda's board. The company states it has substantial cash on hand and is confident in obtaining committed financing for the transaction.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the FDA has declined to approve its New Drug Application (NDA) for tradipitant, a treatment for gastroparesis symptoms. The FDA provided a Complete Response Letter (CRL) on September 18, 2024, 185 days after the submission deadline. Vanda argues that the FDA's action fails to meet the Food Drug and Cosmetic Act requirements and disregards the evidence provided, including two placebo-controlled studies and real-world patient experiences. Despite this setback, Vanda believes tradipitant meets the substantial evidence of efficacy standard and plans to continue pursuing marketing authorization. The company will also maintain its expanded access program for gastroparesis patients and plans to submit a separate NDA for tradipitant in motion sickness prevention later this year.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced its participation in the 2024 Cantor Global Healthcare Conference in New York City on September 19, 2024. The company is scheduled for a fireside chat at 8:00 a.m. Eastern Time. Investors can access the live chat on Vanda's corporate website under the Investors tab and Recent Events section.
Attendees are advised to arrive at the conference website 15 minutes early to register and set up any necessary software. The archived conference will be available on Vanda's website for approximately 30 days following the event.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced its participation in the H.C. Wainwright Global Investment Conference in New York City on September 10, 2024. The company is scheduled to give a corporate presentation at 2:00 p.m. Eastern Time. Investors can access the live presentation through Vanda's corporate website, www.vandapharma.com, by navigating to the Investors tab and following the link under Recent Events.
Attendees are advised to arrive at the conference website 15 minutes early to register and set up any necessary software. The archived presentation will be available on Vanda's website for approximately 30 days after the event.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced its participation in the Wells Fargo 2024 Healthcare Conference in Boston on September 6, 2024. The company's corporate presentation is scheduled for 11:00 a.m. Eastern Time. Investors can access the live presentation through Vanda's corporate website, www.vandapharma.com, by following the link under Recent Events in the Investors tab. It is recommended that investors arrive at the conference website 15 minutes early to register and set up any necessary software. The archived conference will be available on Vanda's website for approximately 30 days after the event.
Vanda Pharmaceuticals reported Q2 2024 financial results with total net product sales of $50.5 million, a 10% increase year-over-year. Key highlights include:
1. Fanapt® net sales of $23.2 million, down 4% YoY but up 12% QoQ
2. HETLIOZ® net sales of $18.7 million, down 15% YoY due to generic competition
3. PONVORY® net sales of $8.6 million, up 26% QoQ
4. Net loss of $4.5 million compared to net income of $1.5 million in Q2 2023
5. Cash position of $387.7 million as of June 30, 2024
Vanda reinstated 2024 financial guidance, projecting total revenues of $180-$210 million and year-end cash of $360-$390 million. The company also highlighted progress in its product pipeline, including the commercial launch of Fanapt® for bipolar I disorder and PONVORY® for multiple sclerosis in Q3 2024.
Vanda Pharmaceuticals (Nasdaq: VNDA) has announced it will release its second quarter 2024 financial results on Wednesday, July 31, 2024, after market close. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using passcode 1278669.
The call will be broadcast live and archived on Vanda's website. A replay will be available from 8:30 PM ET on July 31 until 11:59 PM ET on August 7, 2024. The replay call-in numbers are 1-800-770-2030 (domestic) and 1-609-800-9909 (international), with the same passcode.
Vanda Pharmaceuticals announced that the U.S. District Court for the District of Delaware has allowed its patent lawsuit against Teva Pharmaceuticals and Apotex to proceed. The suit, filed in December 2022, alleges patent infringement related to HETLIOZ®. Teva and Apotex's motions for judgment on the pleadings were denied on June 27, 2024. The court determined that the issues of patentability require further claim construction and fact development. Vanda aims to seek an injunction to stop the defendants from marketing their generic versions of HETLIOZ® until the patent expires.
On June 19, 2024, Vanda Pharmaceuticals (Nasdaq: VNDA) announced its Board of Directors rejected unsolicited takeover proposals from Cycle Group Holdings and Future Pak The offers were $8.00 per share in cash from Cycle Group and $8.50-$9.00 per share in cash plus Contingent Value Rights (CVRs) from Future Pak. The Board determined these proposals undervalue Vanda, citing their clinical development pipeline, commercial presence, and significant cash balance. They deemed the CVRs speculative due to uncertain commercial milestones under Future Pak's management. Vanda remains confident in its long-term growth and value creation potential.
Vanda Pharmaceuticals has received a revised unsolicited takeover proposal from Future Pak, which offers $8.50-$9.00 per share in cash plus Contingent Value Rights. The proposal is currently non-binding. Vanda's Board, consulting with financial and legal advisors, will review this proposal to determine the best course of action for the company and its shareholders.
No immediate action is required from shareholders, and Vanda will not make further comments until the review is complete.
FAQ
What is the current stock price of Vanda Pharma (VNDA)?
What is the market cap of Vanda Pharma (VNDA)?
